ATM protein is deficient in over 40% of lung adenocarcinomas-Reference-Cited by-同舟云学术

ATM protein is deficient in over 40% of lung adenocarcinomas

Published:2016-06-01 Issue:36 Volume:7 Page:57714-57725
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Villaruz Liza C.¹,Jones Helen²,Dacic Sanja³,Abberbock Shira¹,Kurland Brenda F.¹⁴,Stabile Laura P.⁵,Siegfried Jill M.⁶,Conrads Thomas P.⁷,Smith Neil R.²,O’Connor Mark J.²,Pierce Andrew J.²,Bakkenist Christopher J.⁵⁸

Affiliation:

1. University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

2. Astrazeneca, Cambridge, United Kingdom

3. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

4. Department of Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, USA

5. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

6. Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA

7. Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA, USA

8. Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation;Frontiers in Oncology;2024-05-14

2. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review;Translational Lung Cancer Research;2024-02

3. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC;Clinical Cancer Research;2023-09-21

4. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models;Cancers;2023-08-21

5. Variant Characterization of a Representative Large Pedigree Suggests “Variant Risk Clusters” Convey Varying Predisposition of Risk to Lynch Syndrome;Cancers;2023-08-12